Abstract
Patients from historically under-represented racial and ethnic groups are enrolled in cancer clinical trials at disproportionately low rates in the USA1,2,3. As these patients often have limited English proficiency4,5,6,7, we hypothesized that one barrier to their inclusion is the cost to investigators of translating consent documents. To test this hypothesis, we evaluated more than 12,000 consent events at a large cancer centre and assessed whether patients requiring translated consent documents would sign consent documents less frequently in studies lacking industry sponsorship (for which the principal investigator pays the translation costs) than for industry-sponsored studies (for which the translation costs are covered by the sponsor). Here we show that the proportion of consent events for patients with limited English proficiency in studies not sponsored by industry was approximately half of that seen in industry-sponsored studies. We also show that among those signing consent documents, the proportion of consent documents translated into the patient’s primary language in studies without industry sponsorship was approximately half of that seen in industry-sponsored studies. The results suggest that the cost of consent document translation in trials not sponsored by industry could be a potentially modifiable barrier to the inclusion of patients with limited English proficiency.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
All consent-event data associated with this study and data contained in Extended Data tables are freely available at https://doi.org/10.5281/zenodo.7992491.
References
Boulware, L. E. et al. Combating structural inequities—diversity, equity, and inclusion in clinical and translational research. N. Engl. J. Med. 386, 201–203 (2022).
Oyer, R. A. et al. Increasing racial and ethnic diversity in cancer clinical trials: an American Society of Clinical Oncology and Association of Community Cancer Centers joint research statement. J. Clin. Oncol. 40, 2163–2171 (2022).
Wendler, D. et al. Are racial and ethnic minorities less willing to participate in health research? PLoS Med. 3, e19 (2006).
Frayne, S. M., Burns, R. B., Hardt, E. J., Rosen, A. K. & Moskowitz, M. A. The exclusion of non-English-speaking persons from research. J. Gen. Intern. Med. 11, 39–43 (1996).
Glickman, S. W. et al. Perspective: The case for research justice: inclusion of patients with limited English proficiency in clinical research. Acad. Med. 86, 389–393 (2011).
Muthukumar, A. V., Morrell, W. & Bierer, B. E. Evaluating the frequency of English language requirements in clinical trial eligibility criteria: a systematic analysis using ClinicalTrials.gov. PLoS Med. 18, e1003758 (2021).
Roy, M. et al. Limited English proficiency and disparities in health care engagement among patients with breast cancer. JCO Oncol. Pract. 17, e1837–e1845 (2021).
Fleurence, R. L. et al. Engaging patients and stakeholders in research proposal review: the patient-centered outcomes research institute. Ann. Intern. Med. 161, 122–130 (2014).
Staples, J. N. et al. Language as a barrier to cancer clinical trial accrual: assessing consenting team knowledge and practices for cancer clinical trial consent among low English fluency patients. Appl. Cancer Res. 38, 14 (2018).
Clark, L. T. et al. Increasing diversity in clinical trials: overcoming critical barriers. Curr. Probl. Cardiol. 44, 148–172 (2019).
Corbie-Smith, G., Miller, W. C. & Ransohoff, D. F. Interpretations of ‘appropriate’ minority inclusion in clinical research. Am. J. Med. 116, 249–252 (2004).
Davis, T. C., Arnold, C. L., Mills, G. & Miele, L. A qualitative study exploring barriers and facilitators of enrolling underrepresented populations in clinical trials and biobanking. Front. Cell Dev. Biol. 7, 74 (2019).
Murthy, V. H., Krumholz, H. M. & Gross, C. P. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291, 2720–2726 (2004).
Parada, H. Jr., Vu, A. H., Pinheiro, P. S. & Thompson, C. A. Comparing age at cancer diagnosis between Hispanics and non-Hispanic whites in the United States. Cancer Epidemiol. Biomarkers Prev. 30, 1904–1912 (2021).
FDA takes important steps to increase racial and ethnic diversity in clinical trials. US FDA https://www.fda.gov/news-events/press-announcements/fda-takes-important-steps-increase-racial-and-ethnic-diversity-clinical-trials (2022).
Unger, J. M., Vaidya, R., Hershman, D. L., Minasian, L. M. & Fleury, M. E. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. J. Natl Cancer Inst. 111, 245–255 (2019).
Vuong, I. et al. Overcoming barriers: evidence-based strategies to increase enrollment of underrepresented populations in cancer therapeutic clinical trials—a narrative review. J. Cancer Educ. 35, 841–849 (2020).
Ford, J. G. et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer 112, 228–242 (2008).
Durant, R. W. et al. Perspectives on barriers and facilitators to minority recruitment for clinical trials among cancer center leaders, investigators, research staff, and referring clinicians: enhancing minority participation in clinical trials (EMPaCT). Cancer 120, 1097–1105 (2014).
Selected characteristics of the foreign-born population by period of entry into the United States. US Census Bureau https://data.census.gov/cedsci/table?q=AMERICAN%20COMMUNITY%20SURVEY&tid=ACSST5Y2020.S0502 (2020).
Jones, N., Marks, R., Ramirez, R. & Rios-Vargas, M. 2020 census illuminates racial and ethnic composition of the country. US Census Bureau https://www.census.gov/library/stories/2021/08/improved-race-ethnicity-measures-reveal-united-states-population-much-more-multiracial.html (2021).
2019: ACS 1-year estimates selected population profiles. US Census Bureau https://data.census.gov/table?q=Language+Spoken+at+Home&tid=ACSST1Y2019.S1601 (2019).
Zeigler, K. & Camarota, S. A. 67.3 million in the United States spoke a foreign language at home in 2018. Center for Immigration Studies https://cis.org/Report/673-Million-United-States-Spoke-Foreign-Language-Home-2018 (2019).
Department of Health, Education, and Welfare; National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research The Belmont Report. Ethical principles and guidelines for the protection of human subjects of research. J. Am. Coll. Dent. 81, 4–13 (2014).
A guide to informed consent. US FDA https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guide-informed-consent (1998).
Klitzman, R. How US institutional review boards decide when researchers need to translate studies. J. Med. Ethics 40, 193–197 (2014).
McMillan, G. IRB policies for obtaining informed consent from non-English-speaking people. Ethics Hum. Res. 42, 21–29 (2020).
Association, A. T. What is a certified translation? American Translators Association https://www.atanet.org/client-assistance/what-is-a-certified-translation/ (2023).
Mistretta, S. Amending federal regulations to counteract language barriers in the informed consent process. Voices Bioethics https://doi.org/10.52214/vib.v8i.8815 (2022).
Resnik, D. B. & Jones, C. W. Research subjects with limited English proficiency: ethical and legal issues. Account. Res. 13, 157–177 (2006).
Spiegel, M. L. et al. Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges. Cancer 123, 4800–4807 (2017).
Informed consent, draft guidance for IRBs, clinical investigators, and sponsors. US FDA https://www.fda.gov/regulatory-information/search-fda-guidance-documents/informed-consent#nonenglish (2014).
Abadie, A. in Encyclopedia of Social Measurement (ed. Kempf-Leonard, K.) 259–266 (Elsevier, 2005).
Fundytus, A. et al. Industry funding of oncology randomised controlled trials: implications for design, results and interpretation. Clin. Oncol. (R. Coll. Radiol.) 34, 28–35 (2022).
Bodenheimer, T. Uneasy alliance — clinical investigators and the pharmaceutical industry. New Engl. J. Med. 342, 1539–1544 (2000).
Califf, R. M. et al. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007–2010. JAMA 307, 1838–1847 (2012).
Ehrhardt, S., Appel, L. J. & Meinert, C. L. Trends in National Institutes of Health funding for clinical trials registered in ClinicalTrials.gov. JAMA 314, 2566–2567 (2015).
Hakoum, M. B. et al. Characteristics of funding of clinical trials: cross-sectional survey and proposed guidance. BMJ Open 7, e015997 (2017).
Nevens, H. et al. Budgeting of non-commercial clinical trials: development of a budget tool by a public funding agency. Trials 20, 714 (2019).
Marshall, A. Principles of Economics: An Introductory Volume 8th edn (Macmillan, 1920).
Fischer, A., Conigliaro, J., Allicock, S. & Kim, E. J. Examination of social determinants of health among patients with limited English proficiency. BMC Res. Notes 14, 299 (2021).
Proctor, K., Wilson-Frederick, S. M. & Haffer, S. C. The limited English proficient population: describing medicare, medicaid, and dual beneficiaries. Health Equity 2, 82–89 (2018).
Quick facts. US Census Bureau https://www.census.gov/quickfacts/fact/table/US# (2022).
Schilsky, R. L. Publicly funded clinical trials and the future of cancer care. The Oncologist 18, 232–238 (2013).
NIH policy and guidelines on the inclusion of women and minorities as subjects in clinical research. NIH https://grants.nih.gov/policy/inclusion/women-and-minorities/guidelines.htm (1993).
Schmidt, C. Cooperative groups say NCI trials funding inadequate; some turn to industry. J. Natl Cancer Inst. 99, 830–837 (2007).
Txabarriaga, R. IMIA Guide on Medical Translation, https://www.imiaweb.org/uploads/pages/438.pdf (IMIA, 2009); .
Brelsford, K. M., Ruiz, E. & Beskow, L. Developing informed consent materials for non-English-speaking participants: an analysis of four professional firm translations from English to Spanish. Clin. Trials 15, 557–566 (2018).
Staff, A. C. California: 2020 census. US Census Bureau https://www.census.gov/library/stories/state-by-state/california-population-change-between-census-decade.html#:~:text=Race%20and%20ethnicity%20(White%20alone,or%20More%20Races%2010.2%25) (2020).
Harris, P. A. et al. The REDCap consortium: building an international community of software platform partners. J. Biomed. Inform. 95, 103208 (2019).
Harris, P. A. et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42, 377–381 (2009).
Acknowledgements
We thank J. Allen and R. Flores Stella for their assistance. E.B.G. was funded by NIH-NCI R01 CA276917, the Cancer Center Support Grant P30 CA016042, and NIH-NCATS UL1TR001881, CLIN-10784. A.L.C. was funded by a Specialty Training and Advanced Research (STAR) Award. A.L. was funded by NIH-NCI K08 CA245249-01A1 and a LUNGevity 2019 Career Development Award. E.B.G. is also funded by CLIN-10784. M.A.T. was funded by P30 CA016042- Cancer Center Support Grant, UCLA Jonsson Comprehensive Cancer Center. D.E. was funded by the National Center for Advancing Translational Science (NCATS) of the National Institutes of Health under the UCLA Clinical and Translational Science Institute grant number UL1TR001881. Figure 1 was created using BioRender.com. This work was funded by E.B.G.’s UCLA Jonsson Comprehensive Cancer Center Seed Grant.
Author information
Authors and Affiliations
Contributions
M.A.V., B.A.G. and E.B.G. contributed substantially to the conception and design of the work. M.A.V., A.N., Y.R., J.P.L.-L., P.M.B., D.Y.L., M.J.F.-T., M.L., M.H., J.B., T.G., D.E. and E.B.G. contributed to data acquisition, analysis and interpretation. M.A.V. and E.B.G. drafted the paper. B.A.G., A.L.C., M.G.-J., A.G., M.A.T., A.L. and E.B.G. contributed substantially to paper revision.
Corresponding author
Ethics declarations
Competing interests
E.B.G. has been a consultant and/or advisor for Abbvie; ABL-Bio; AstraZeneca, Boehringer-Ingelheim; Bristol-Myers Squibb; Dracen Pharmaceuticals; EMD Serono; Eisai; Eli Lilly; Gilead; GlaxoSmithKline; Ipsen; Merck; Natera; Novartis; Personalis; Regeneron; Sanofi; Shionogi; and Xilio. E.B.G. has received grant or research support from ABL-Bio; AstraZeneca; Bristol-Myers Squibb; Dynavax Technologies; Eli Lilly; EMD Serono; Genentech; Iovance Biotherapeutics; Merck; Mirati Therapeutics; Neon; and Novartis. A.L. has received commercial research grants from Daiichi Sankyo, Calithera Biosciences, AstraZeneca, Dracen Pharmaceuticals, WindMIL, eFFECTOR Therapeutics. A.E.L. has served as a consultant or on the advisory board for, AstraZeneca, Bristol-Myers Squibb, Leica Biosystems, Jazz Pharmaceuticals, Novocure, Pfizer, MorphoSys, Eli Lilly, Oncocyte, Novartis, Regeneron, Janssen oncology, Sanofi group of companies. M.A.V., B.A.G., M.G.-J., A.N., Y.R., J.P.L.-L., P.M.B., D.Y.L., M.J.F.-T., A.G., M.L., M.H., J.B. and T.G. declare no competing interests.
Peer review
Peer review information
Nature thanks Jason Abaluck, Jan Eberth and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data figures and tables
Extended Data Fig. 1 Comparison of the proportion of consent events based on primary language and English proficiency in interventional industry versus non-industry sponsored studies.
a. Blue indicates the proportion of consent events for patients with English as their primary language. Yellow indicates the proportion of consent events for patients with a primary language other than English in industry sponsored studies (top bar) versus non-industry sponsored studies (bottom bar) (8.2% versus 4.0%, p < 0.001). b. Blue indicates the proportion of consent events for patients with English as their primary language. Red indicates the proportion of consent events for patients with limited English proficiency in industry sponsored studies (top bar) versus non-industry sponsored studies (bottom bar) (5.6% versus 2.5%, p < 0.001). Logistic regression models with Generalized Estimating Equations clustered by patient unique identifier were used to test comparisons above, P values reported are two-tailed.
Extended Data Fig. 2 Comparison of the percentage of patients signing consent documents per study between industry and non-industry sponsored studies.
The X axis depicts the percentage of patients signing consent documents for each study who had a primary language other than English in industry (a) and non-industry sponsored studies (b). Each study is represented by a row in the Y axis. The rows are taller for non-industry sponsored studies compared to industry sponsored studies as there are fewer of them. Green denotes the percentage of patients who signed consent in their primary language, pink represents the percentage of patients signing consent documents in a language different than their primary language and red represents the percentage of patients with limited English proficiency signing consent document in a language different than primary.
Supplementary information
Supplementary Methods
This file includes further information about the study population, definitions of groups and subgroups, definitions of primary language and limited English proficiency, correct versus incorrect language in which patients signed consent documents, and variables included in statistical analyses as well as handling of missing data.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Velez, M.A., Glenn, B.A., Garcia-Jimenez, M. et al. Consent document translation expense hinders inclusive clinical trial enrolment. Nature 620, 855–862 (2023). https://doi.org/10.1038/s41586-023-06382-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41586-023-06382-0
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
